R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Pharma waste management: Balancing cost, compliance, and env...

In an era where healthcare advancements are at their peak, an often overlooked, yet critical, aspect is the management of pharmaceutical waste.

R&D

JP Morgan 2024 – Graham Heap

Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.

R&D

Abstract laptop with coloured DNA molecule

Understanding the impact of AI on the advancement of gene th...

The biopharmaceutical landscape stands at the cusp of a transformative era, with artificial intelligence (AI) leading the charge.

R&D

Why Scotland is well-positioned to lead in advanced therapie...

The global health burden of complex diseases such as severe lung, liver, and vascular disease is huge, and growing by the second.

R&D

This week in clinical trials: 8th-12th January

In our second clinical trials update of 2024, taking in developments in life sciences research and development from early-stage onwards, we look at a wide range of announcements – from onco

R&D

JP Morgan 2024 – Jeff Smith

Editor-in-chief Jonah Comstock sat down with Jeff Smith, chief research officer at Precision BioSciences, on the side lines of the JP Morgan Healthcare Conference in San Francisco to discus